Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data.

CONCLUSION: Rivaroxaban seems a safe and effective therapeutic option in CKD stage 3b-4 patients. However, future randomized controlled trials are needed to definitively establish the role of rivaroxaban in CKD patients.
PMID: 29882198 [PubMed - as supplied by publisher]

Source: Journal of Nephrology - June 7, 2018 Category: Urology & Nephrology Authors: Di Lullo L, Tripepi G, Ronco C, De Pascalis A, Barbera V, Granata A, Russo D, Di Iorio BR, Paoletti E, Ravera M, Fusaro M, Bellasi A Tags: J Nephrol Source Type: research